However, recent studies have demonstrated that these cases are better classified as “B-acute lymphoblastic leukemia (B-ALL) with MYC rearrangement.” [25, 51, 52] B-ALL with MYC rearrangement is recognized in the 2022 ICC as a specific entity [25] and is included in the 5th WHO classification within the group of “B-ALL with other rearrangements.” [26] The disease affects mostly male patients (range 3–75 years), and the tumor cells have an immature phenotype, often with expression of TdT and CD10 without CD20, BCL6 and sIg; however lack CD34. The gene discussed is BCL6; the disease is neoplasm.